

# Notice of Allowability

Application No.

10/049,645

Examiner

Rebecca L Anderson

Applicant(s)

MIYACHI ET AL.

Art Unit

1626

## -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment and declaration filed 23 September 2003.
2. ☒ The allowed claim(s) is/are 1-9, 22 and 23, now renumbered 1-11.
3. ☐ The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☒ All b) ☐ Some\* c) ☐ None of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. ☒ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
  - \* Certified copies not received: \_\_\_\_\_.
5. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
  - (a) ☐ The translation of the foreign language provisional application has been received.
6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
  - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
    - 1) ☐ hereto or 2) ☐ to Paper No. \_\_\_\_\_.
  - (b) ☐ including changes required by the proposed drawing correction filed \_\_\_\_\_, which has been approved by the Examiner.
  - (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).

9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

## Attachment(s)

- |  |  |
|--|--|
| <input type="checkbox"/> Notice of References Cited (PTO-892)  | <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)                 |
| <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | <input checked="" type="checkbox"/> Interview Summary (PTO-413), Paper No. <u>1203</u> . |
| <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No. <u>23 Sept 03</u> | <input checked="" type="checkbox"/> Examiner's Amendment/Comment                         |
| <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material                       | <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance        |
|  | <input type="checkbox"/> Other   |

### **DETAILED ACTION**

Claims 1-9, 22 and 23 are currently pending in the instant application, are allowable over the prior art of record and have been renumbered as claims 1-11. Claim 23 drawn to a process for the preparation of a medicinal composition of claim 1 has been rejoined.

### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Tom Barnes on 3 December 2003.

The application has been amended as follows:

Specification:

1. Insert --This application is a 371 of PCT/JP00/05519 filed 18 August 2000.-- below the line that states "Technical Field" and above the line that states "The present invention relates to substituted" found on page 1 of the instant specification.

Claims:

1. Cancel claims 13-21.
2. Amend claim 23 by inserting --for preparing a medicinal composition-- after "A process" and before the comma on line 1 of claim 23.
3. Cancel claim 24.

***Information Disclosure Statement***

The information disclosure statement (IDS) submitted on 27 May 2003 discloses the copending application 10/049904. This co-pending application has been considered but will not be printed on the front of a patent issuing off of this application.

***Reasons for Allowance***

The following is an examiner's statement of reasons for allowance. This invention relates to benzylthiazolidine-2,4-dione products. The novel and nonobvious aspect of this invention involves the methoxy substituent on the benzyl group and the linking group A. The closest prior art of record fails to teach or suggest the instant benzylthiazolidine-2,4-dione products which have an unexpected dual agonist activity on PPAR alpha and gamma .

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

**Conclusion**

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (703) 605-1157. Mrs. Anderson can normally be reached Monday through Friday 6:00AM to 2:30PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph McKane, can be reached at (703) 308-4537.


Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone numbers are (703) 308-1235 and (703) 308-0196.

A facsimile center has been established. The hours of operation are Monday through Friday, 8:45AM to 4:45PM. The telecopier number for accessing the facsimile machine is (703) 872-9306.



---

Rebecca Anderson  
Patent Examiner  
Art Unit 1626, Group 1620  
Technology Center 1600



---

Joseph McKane  
Supervisory Patent Examiner  
Art Unit 1626, Group 1620  
Technology Center 1600